PARP1 and cancer: Recent studies indicate that regardless of BRCA1/2 status, inhibiting BRD4 with BETi decreases the expression of the DNA repair factor CtIP, inducing HR defects and enhancing DNA damage induced by PARP inhibitors in cancer cells (152).